经济观察网截至2026年2月13日，太美医疗科技(02576.HK)近期有以下值得关注的事件动态： 高管变动 2026年1月22日，董事会已决议建议采纳2026年H股奖励计划，并计划向63名参与者首次授予合计约 2004万份奖励。该计划仍需在临时股东大会上获得股东批准后方可生效。 以上内容基于公开资料整理，不构成投资建议。 公司项目推进 2025年12月24日，公司作为有限合伙人与其他多方共同设立合伙企业，初始注资总额为人民币2.27亿 元，其中公司出资7000万元。该合伙企业将优先投资于位于嘉兴经济技术开发区的创新药研发公司，旨 在通过输出其数智化解决方案参与早期创新药管线投资。 业绩经营情况 根据2025年中期报告，公司上半年营业收入为2.44亿元，同比下降10.47%，净亏损为2280.2万元，较上 年同期有所收窄。2024年全年业绩显示，经调整亏损同比收窄81.9%，毛利率提升9.6个百分点至 40.8%。 行业地位 公司在2024年连续第四年在中国临床试验信息系统市场份额排名第一。2025年，其AI智能体实践入选 浙江省人工智能应用场景名单，Trials智能临床研究协作平台入选首批"浙江省制造业单项 ...

Group 1 - The first batch of "Zhejiang Province Manufacturing Single Champion Enterprises" has been announced, with Taimei Medical Technology's "Trials Intelligent Clinical Research Collaboration Platform" included in the list [1] - The selection criteria focused on the level of specialized development, core technological innovation capabilities, market competitiveness, and quality efficiency of the enterprises [1] - The Trials platform integrates a full range of digital solutions for clinical research, enhancing collaboration across organizations and significantly improving overall efficiency in pharmaceutical research [1] Group 2 - According to IDC China's latest report, Taimei Medical Technology ranks first in the Chinese clinical trial information system market share for 2024, marking the fourth consecutive year at the top [2] - The company aims to continue its vision of "releasing digital intelligence power to make health accessible" by enhancing core technology development and maintaining its leading edge in technological innovation and service upgrades [2] - Taimei Medical Technology is focused on building the next-generation digital infrastructure for the pharmaceutical industry, driving industry transformation and contributing to the high-quality development of the pharmaceutical sector in China [2]